Pandeia Therapeutics (@PandeiaT) is an Oxford based, venture backed startup. Pandeia is developing first in class GPR88 agonists for the treatment of motor symptoms associated with Huntington’s Disease (HD). GPR88 has strong genetic validation as a target for HD, as well as other CNS disorders. Pandeia molecules have shown a superior efficacy and side effect profile to current standard of care in animal models of HD. Pandeia anticipates nominating a development candidate in 1H 2022.